MCM
BHVN

Moore Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Moore Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-80,856
Closed -$4.4M – 312
2019
Q4 		$4.4M Sell
80,856
-39,839
-33% -$1.97M 0.14% 149
2019
Q3 		$5.04M Buy
120,695
+50,695
+72% +$2.14M 0.2% 142
2019
Q2 		$3.06M Buy
+70,000
New +$3.95M 0.07% 207

Other funds holding BHVN

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Moore Capital Management's BHVN Position: Q1 2020 in Review

Moore Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2020, closing a stake of 80,856 shares — an estimated $4.4M sold.

Moore Capital Management first reported a position in BHVN in Q2 2019 and held it in 3 quarters. The position peaked at $5.04M in Q3 2019. 175 funds tracked by Wall St. Rank hold BHVN as of Q1 2020.

  • Moore Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2020 after selling out during the quarter.
  • Moore Capital Management sold 80,856 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2020, an estimated $4.4M.
  • Moore Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019 and held it in 3 quarters.
  • Moore Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $5.04M in Q3 2019.
  • 175 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2020.

Based on Moore Capital Management's 13F filing for Q1 2020, filed 15 May 2020.